Literature DB >> 25982274

miR-520h is crucial for DAPK2 regulation and breast cancer progression.

C-M Su1,2, M-Y Wang3, C-C Hong4, H-A Chen1,2, Y-H Su2, C-H Wu1,2, M-T Huang2, Y-W Chang4, S-S Jiang4, S-Y Sung5, J-Y Chang4, L-T Chen4, P-S Chen6,7, J-L Su4,8,9,10.   

Abstract

MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3'untranslated region of specific target mRNAs. Although the dysregulation of miRNAs has been identified in human cancer, only a few of these miRNAs have been functionally documented in breast cancer. Thus, defining the important miRNA and functional target involved in chemoresistance is an urgent need for human breast cancer treatment. In this study, we, for the first time, identified a key role of miRNA 520h (miR-520h) in drug resistance. Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. Bioinformatics prediction, compensatory mutation and functional validation further confirmed the essential role of miR-520h-suppressed Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. Furthermore, we observed that higher level of miR-520h is associated with poor prognosis and lymph node metastasis in human breast cancer patients. These results show that miR-520h is not only an independent prognostic factor, but is also a potential functional target for future applications in cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25982274     DOI: 10.1038/onc.2015.168

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

Review 1.  Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.

Authors:  José Baselga
Journal:  Oncologist       Date:  2011

Review 2.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 3.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

Review 4.  Role of microRNA in anticancer drug resistance.

Authors:  Tongsen Zheng; Jiabei Wang; Xi Chen; Lianxin Liu
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

5.  Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms.

Authors:  G V Glinsky; V V Glinsky; A B Ivanova; C J Hueser
Journal:  Cancer Lett       Date:  1997-05-19       Impact factor: 8.679

6.  Molecular pathways: PI3K pathway targets in triple-negative breast cancers.

Authors:  Vallerie Gordon; Shantanu Banerji
Journal:  Clin Cancer Res       Date:  2013-06-07       Impact factor: 12.531

7.  miR-21-mediated tumor growth.

Authors:  M-L Si; S Zhu; H Wu; Z Lu; F Wu; Y-Y Mo
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

8.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

9.  Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over.

Authors:  F M-S Barthel; A Babiker; P Royston; M K B Parmar
Journal:  Stat Med       Date:  2006-08-15       Impact factor: 2.373

10.  MicroRNA-mediated drug resistance in breast cancer.

Authors:  Kristy R Kutanzi; Olga V Yurchenko; Frederick A Beland; Vasyl' F Checkhun; Igor P Pogribny
Journal:  Clin Epigenetics       Date:  2011-06-27       Impact factor: 6.551

View more
  20 in total

Review 1.  MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer.

Authors:  Zhipin Liang; Yaguang Xi
Journal:  Chin J Nat Med       Date:  2016-12

Review 2.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

3.  MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion.

Authors:  Xiaomei Su; Ling Zhang; Hua Li; Peng Cheng; Yajie Zhu; Zhen Liu; Yu Zhao; Hongyu Xu; Dong Li; Hui Gao; Tao Zhang
Journal:  Oncol Lett       Date:  2017-01-25       Impact factor: 2.967

4.  Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells.

Authors:  Szu-Yuan Wu; Alexander T H Wu; Kevin Sheng-Po Yuan; Shing Hwa Liu
Journal:  J Cancer       Date:  2016-12-09       Impact factor: 4.207

5.  IGF-1-mediated PKM2/β-catenin/miR-152 regulatory circuit in breast cancer.

Authors:  Yi-Yang Wen; Wei-Tao Liu; Hao-Ran Sun; Xin Ge; Zhu-Mei Shi; Min Wang; Wei Li; Jian-Ying Zhang; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Sci Rep       Date:  2017-11-21       Impact factor: 4.379

Review 6.  Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.

Authors:  Alma D Campos-Parra; Gerardo Cuamani Mitznahuatl; Abraham Pedroza-Torres; Rafael Vázquez Romo; Fany Iris Porras Reyes; Eduardo López-Urrutia; Carlos Pérez-Plasencia
Journal:  Int J Mol Sci       Date:  2017-06-02       Impact factor: 5.923

Review 7.  Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

Authors:  Nina Petrović; Irina Nakashidze; Milica Nedeljković
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-01-21       Impact factor: 2.673

8.  MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.

Authors:  Jing Zhang; Lei Liu; Yunyan Sun; Jiandong Xiang; Dongmei Zhou; Li Wang; Huali Xu; Xiaoming Yang; Na Du; Meng Zhang; Qin Yan; Xiaowei Xi
Journal:  Oncotarget       Date:  2016-05-03

9.  MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44.

Authors:  Ya-Ching Lu; Ann-Joy Cheng; Li-Yu Lee; Guo-Rung You; Yan-Liang Li; Hsin-Ying Chen; Joseph T Chang
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

10.  First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Katarina Ivankova; Ladislav Krofta
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.